Main Article Content
OBJECTIVES: To study the prevalence of MYC/BCL2 double expression in diffuselarge B-cell lymphomas (DLBCLs) and its prognostic value.
MATERIAL AND METHODS: This is a retrospective observational study, which includespatients diagnosed with DLBCLs at King Chulalongkorn Memorial Hospital from 2013 to2014. The slides were reviewed, and MYC and BCL2 immunostains were scored accordingto Revised WHO 2016 Classification. Clinical data were collected from medical records.Patients were divided into two groups: double expression (DE) and non-double expression(NDE). Survivals and hazard ratios (HR) were calculated.
RESULTS: Eighty-eight patients were included in the study and 40 (46%) had doubleexpression. The mean age was 60±16 years old; 40.9% were male and 59.1% werefemale. Eight patients were excluded from the survival analysis due to incompleteclinical data. Of the remaining 80 patients, there were 34 (42.5%) DE and 46 (57.5%)NDE. Median overall survival time (OS) and median progression-free survival time(PFS) tended to be lower in the DE group but was not statistically significant (Log-ranktest, p = 0.16). Multivariate analysis identified 4 confounders: sex, cell of origin (COO),risk group and addition of rituximab to the standard treatment. Adjusted HRs of the DEgroup were 1.21 (95%CI 0.63-2.31, p = 0.57) for OS and 1.20 (95%CI 0.63-2.30,p = 0.58) for PFS. In the germinal center subgroup (GCB) of DLBCL, patients with DEhad HRs of 4.33 (95%CI 0.80-23.37, p = 0.08, significance level of p < 0.10) for OS and4.61 (95%CI 0.80-23.37, p = 0.08) for PFS; but, these were not significant in the non-GCBsubgroup.
CONCLUSION: MYC/BCL2 double expression (DE) is significantly associated withpoorer prognosis than non-double expression (NDE) among DLBCLs with GCBphenotype. MYC/BCL2 double expression should be reported in the pathologicaldiagnosis of DLBCLs.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Bunworasate U, Siritanaratanakul N, Khuhapinant A, et al. A nationwide prospective multicenter study of clinical features and outcomes of non-Hodgkin lymphoma in Thailand: an analysis of 939 Cases. Blood 2011;118:2064.
3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendationsfor Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classiﬁcation. J Clin Oncol 2014;32:3059-67.
4. Moccia AA, Donaldson J, Chhanabhai M, et al. International prognostic score in advanced-Stage Hodgkin’s Lymphoma: Altered Utility in the Modern Era. J Clin Oncol 2012;30:3383-8.
5. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-94.
6. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21(2):266-72.
7. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103(1):275-82.
9. Aukema SM, Siebert R, Schuuring E. et al. Double-hit B-cell lymphomas. Blood 2011;117(8):2319-31.
10. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34(3):327-40.
11. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375-90.
12. Green TM, Nielsen O, de Stricker K, et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012;36(4):612-9.
13. Johnson NA, Slack GW, Savage KJ, et al. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol 2012;30(28):3452-9.
14. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30(28):3460-7.
15. Jing Wang, Min Zhou, Jing-Yan Xu, et al. Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma. Onco Targets Ther 2015;8:2645-50.
16. Xia B, Zhang L, Guo SQ, et al. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cel l lymphoma. World J Gastroenterol 2015;21(8):2433-42.
17. Hattab EM, Martin SE, Al-Khatib SM, et al. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol 2010;23:235-43.
18. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121(20):4021-31.
19. Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood 2017;129(3):280-8.